International comparison of the relationship of chronic kidney disease prevalence and ESRD risk

Stein I. Hallan, Josef Coresh, Brad C. Astor, Arne Åsberg, Neil R. Powe, Solfrid Romundstad, Hans A. Hallan, Stian Lydersen, Jostein Holmen

Research output: Contribution to journalArticle

Abstract

ESRD incidence is much lower in Europe compared with the United States. This study investigated whether this reflects a difference in the prevalence of earlier stages of chronic kidney disease (CKD) or other mechanisms. CKD prevalence in Norway was estimated from the population-based Health Survey of Nord-Trondelag County (HUNT II), which included 65,181 adults in 1995 through 1997 (participation rate 70.4%). Data were analyzed using the same methods as two US National Health and Nutrition Examination Surveys in 1988 through 1994 (n = 15,488) and 1999 through 2000 (n = 4101). The primary analysis used gender-specific cutoffs in estimating persistent albuminuria for CKD stages 1 and 2. ESRD rates and other relevant data were extracted from national registries. Total CKD prevalence in Norway was 10.2% (SE 0.5): CKD stage 1 (GFR >90 ml/min per 1.73 m2 and albuminuria), 2.7% (SE 0.3); stage 2 (GFR 60 to 89 ml/min per 1.73 m2 and albuminuria), 3.2% (SE 0.4); stage 3 (GFR 30 to 59 ml/min per 1.73 m2), 4.2% (SE 0.1); and stage 4 (GFR 15 to 29 ml/min per 1.73 m2), 0.2% (SE 0.01). This closely approximates reported US CKD prevalence (11.0% in 1988 through 1994 and 11.7% in 1999 through 2000). The relative risk for progression from CKD stages 3 or 4 to ESRD in US white patients compared with Norwegian patients was 2.5. This was only modestly modified by adjustment for age, gender, and diabetes. Age and GFR at start of dialysis were similar, hypertension and cardiovascular mortality in the populations were comparable, but US white patients were referred later to a nephrologist and had higher prevalence of obesity and diabetes. In conclusion, CKD prevalence in Norway was similar to that in the United States, suggesting that lower progression to ESRD rather than a smaller pool of individuals at risk accounts for the lower incidence of ESRD in Norway.

Original languageEnglish (US)
Pages (from-to)2275-2284
Number of pages10
JournalJournal of the American Society of Nephrology
Volume17
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Chronic Renal Insufficiency
Chronic Kidney Failure
Norway
Albuminuria
Nutrition Surveys
Incidence
Health Surveys
Population
Registries
Dialysis
Obesity
Hypertension
Mortality

ASJC Scopus subject areas

  • Nephrology

Cite this

International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. / Hallan, Stein I.; Coresh, Josef; Astor, Brad C.; Åsberg, Arne; Powe, Neil R.; Romundstad, Solfrid; Hallan, Hans A.; Lydersen, Stian; Holmen, Jostein.

In: Journal of the American Society of Nephrology, Vol. 17, No. 8, 08.2006, p. 2275-2284.

Research output: Contribution to journalArticle

Hallan, SI, Coresh, J, Astor, BC, Åsberg, A, Powe, NR, Romundstad, S, Hallan, HA, Lydersen, S & Holmen, J 2006, 'International comparison of the relationship of chronic kidney disease prevalence and ESRD risk', Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2275-2284. https://doi.org/10.1681/ASN.2005121273
Hallan, Stein I. ; Coresh, Josef ; Astor, Brad C. ; Åsberg, Arne ; Powe, Neil R. ; Romundstad, Solfrid ; Hallan, Hans A. ; Lydersen, Stian ; Holmen, Jostein. / International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. In: Journal of the American Society of Nephrology. 2006 ; Vol. 17, No. 8. pp. 2275-2284.
@article{8573901643c84ecda13a1442eee3da37,
title = "International comparison of the relationship of chronic kidney disease prevalence and ESRD risk",
abstract = "ESRD incidence is much lower in Europe compared with the United States. This study investigated whether this reflects a difference in the prevalence of earlier stages of chronic kidney disease (CKD) or other mechanisms. CKD prevalence in Norway was estimated from the population-based Health Survey of Nord-Trondelag County (HUNT II), which included 65,181 adults in 1995 through 1997 (participation rate 70.4{\%}). Data were analyzed using the same methods as two US National Health and Nutrition Examination Surveys in 1988 through 1994 (n = 15,488) and 1999 through 2000 (n = 4101). The primary analysis used gender-specific cutoffs in estimating persistent albuminuria for CKD stages 1 and 2. ESRD rates and other relevant data were extracted from national registries. Total CKD prevalence in Norway was 10.2{\%} (SE 0.5): CKD stage 1 (GFR >90 ml/min per 1.73 m2 and albuminuria), 2.7{\%} (SE 0.3); stage 2 (GFR 60 to 89 ml/min per 1.73 m2 and albuminuria), 3.2{\%} (SE 0.4); stage 3 (GFR 30 to 59 ml/min per 1.73 m2), 4.2{\%} (SE 0.1); and stage 4 (GFR 15 to 29 ml/min per 1.73 m2), 0.2{\%} (SE 0.01). This closely approximates reported US CKD prevalence (11.0{\%} in 1988 through 1994 and 11.7{\%} in 1999 through 2000). The relative risk for progression from CKD stages 3 or 4 to ESRD in US white patients compared with Norwegian patients was 2.5. This was only modestly modified by adjustment for age, gender, and diabetes. Age and GFR at start of dialysis were similar, hypertension and cardiovascular mortality in the populations were comparable, but US white patients were referred later to a nephrologist and had higher prevalence of obesity and diabetes. In conclusion, CKD prevalence in Norway was similar to that in the United States, suggesting that lower progression to ESRD rather than a smaller pool of individuals at risk accounts for the lower incidence of ESRD in Norway.",
author = "Hallan, {Stein I.} and Josef Coresh and Astor, {Brad C.} and Arne {\AA}sberg and Powe, {Neil R.} and Solfrid Romundstad and Hallan, {Hans A.} and Stian Lydersen and Jostein Holmen",
year = "2006",
month = "8",
doi = "10.1681/ASN.2005121273",
language = "English (US)",
volume = "17",
pages = "2275--2284",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - International comparison of the relationship of chronic kidney disease prevalence and ESRD risk

AU - Hallan, Stein I.

AU - Coresh, Josef

AU - Astor, Brad C.

AU - Åsberg, Arne

AU - Powe, Neil R.

AU - Romundstad, Solfrid

AU - Hallan, Hans A.

AU - Lydersen, Stian

AU - Holmen, Jostein

PY - 2006/8

Y1 - 2006/8

N2 - ESRD incidence is much lower in Europe compared with the United States. This study investigated whether this reflects a difference in the prevalence of earlier stages of chronic kidney disease (CKD) or other mechanisms. CKD prevalence in Norway was estimated from the population-based Health Survey of Nord-Trondelag County (HUNT II), which included 65,181 adults in 1995 through 1997 (participation rate 70.4%). Data were analyzed using the same methods as two US National Health and Nutrition Examination Surveys in 1988 through 1994 (n = 15,488) and 1999 through 2000 (n = 4101). The primary analysis used gender-specific cutoffs in estimating persistent albuminuria for CKD stages 1 and 2. ESRD rates and other relevant data were extracted from national registries. Total CKD prevalence in Norway was 10.2% (SE 0.5): CKD stage 1 (GFR >90 ml/min per 1.73 m2 and albuminuria), 2.7% (SE 0.3); stage 2 (GFR 60 to 89 ml/min per 1.73 m2 and albuminuria), 3.2% (SE 0.4); stage 3 (GFR 30 to 59 ml/min per 1.73 m2), 4.2% (SE 0.1); and stage 4 (GFR 15 to 29 ml/min per 1.73 m2), 0.2% (SE 0.01). This closely approximates reported US CKD prevalence (11.0% in 1988 through 1994 and 11.7% in 1999 through 2000). The relative risk for progression from CKD stages 3 or 4 to ESRD in US white patients compared with Norwegian patients was 2.5. This was only modestly modified by adjustment for age, gender, and diabetes. Age and GFR at start of dialysis were similar, hypertension and cardiovascular mortality in the populations were comparable, but US white patients were referred later to a nephrologist and had higher prevalence of obesity and diabetes. In conclusion, CKD prevalence in Norway was similar to that in the United States, suggesting that lower progression to ESRD rather than a smaller pool of individuals at risk accounts for the lower incidence of ESRD in Norway.

AB - ESRD incidence is much lower in Europe compared with the United States. This study investigated whether this reflects a difference in the prevalence of earlier stages of chronic kidney disease (CKD) or other mechanisms. CKD prevalence in Norway was estimated from the population-based Health Survey of Nord-Trondelag County (HUNT II), which included 65,181 adults in 1995 through 1997 (participation rate 70.4%). Data were analyzed using the same methods as two US National Health and Nutrition Examination Surveys in 1988 through 1994 (n = 15,488) and 1999 through 2000 (n = 4101). The primary analysis used gender-specific cutoffs in estimating persistent albuminuria for CKD stages 1 and 2. ESRD rates and other relevant data were extracted from national registries. Total CKD prevalence in Norway was 10.2% (SE 0.5): CKD stage 1 (GFR >90 ml/min per 1.73 m2 and albuminuria), 2.7% (SE 0.3); stage 2 (GFR 60 to 89 ml/min per 1.73 m2 and albuminuria), 3.2% (SE 0.4); stage 3 (GFR 30 to 59 ml/min per 1.73 m2), 4.2% (SE 0.1); and stage 4 (GFR 15 to 29 ml/min per 1.73 m2), 0.2% (SE 0.01). This closely approximates reported US CKD prevalence (11.0% in 1988 through 1994 and 11.7% in 1999 through 2000). The relative risk for progression from CKD stages 3 or 4 to ESRD in US white patients compared with Norwegian patients was 2.5. This was only modestly modified by adjustment for age, gender, and diabetes. Age and GFR at start of dialysis were similar, hypertension and cardiovascular mortality in the populations were comparable, but US white patients were referred later to a nephrologist and had higher prevalence of obesity and diabetes. In conclusion, CKD prevalence in Norway was similar to that in the United States, suggesting that lower progression to ESRD rather than a smaller pool of individuals at risk accounts for the lower incidence of ESRD in Norway.

UR - http://www.scopus.com/inward/record.url?scp=33746508501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746508501&partnerID=8YFLogxK

U2 - 10.1681/ASN.2005121273

DO - 10.1681/ASN.2005121273

M3 - Article

C2 - 16790511

AN - SCOPUS:33746508501

VL - 17

SP - 2275

EP - 2284

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -